Use of nebulised liposomal amphotericin B in the treatment of Aspergillus fumigatus empyema.
AUTOR(ES)
Purcell, I F
RESUMO
A 28 year old man with asthma, bronchopulmonary aspergillosis, pulmonary thromboembolic disease, and pulmonary hypertension developed Aspergillus fumigatus empyema complicating a pneumothorax. His condition progressively deteriorated despite treatment with intravenous and intrapleural amphotericin B, but improved promptly after substituting nebulised liposomal amphotericin B and oral itraconazole. This experience suggests that nebulised liposomal amphotericin B is well tolerated and merits further assessment in the treatment of pulmonary fungal disease.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1021361Documentos Relacionados
- Dose Range Evaluation of Liposomal Nystatin and Comparisons with Amphotericin B and Amphotericin B Lipid Complex in Temporarily Neutropenic Mice Infected with an Isolate of Aspergillus fumigatus with Reduced Susceptibility to Amphotericin B
- Suction drainage: a new approach to the treatment of empyema.
- The use of voriconazole in the treatment of Aspergillus fumigatus keratitis
- Trichomonas empyema.
- Efficacy of Liposomal Amphotericin B in Treatment of Systemic Murine Fusariosis
